Literature DB >> 10342709

Apheresis for lupus erythematosus.

D J Wallace1.   

Abstract

Indications for the use of apheresis technologies in managing lupus erythematosus have undergone numerous conceptual changes since the procedure was automated in the 1960s and first attempted for systemic lupus erythematosus (SLE) in 1974. Once thought to be a promising treatment for a variety of aspects of SLE, apheresis has been relegated to occupying a few important niches as an adjunct in managing the disorder. This article will review the history, physiology and rationale of apheresis pertaining to SLE. A focused critical review of pertinent literature is presented, along with specific recommendations relating to the place of apheresis in the lupus therapeutic spectrum.

Entities:  

Mesh:

Year:  1999        PMID: 10342709     DOI: 10.1191/096120399678847669

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

1.  Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy.

Authors:  Chems Gharbi; Edward Bourry; Philippe Rouvier; Sabria Hacini; Ahmed Letaief; Alain Baumelou; Hassane Izzedine
Journal:  Clin Exp Nephrol       Date:  2010-06-11       Impact factor: 2.801

2.  IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.

Authors:  G H Stummvoll; M Aringer; J S Smolen; S Schmaldienst; E Jiménez-Boj; W H Hörl; W B Graninger; K Derfler
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

3.  Lupus vasculopathy combined with acute renal failure in lupus nephritis.

Authors:  Chien-Te Wu; Lin-Shien Fu; Mei-Chin Wen; Shein-Chung Hung; Ching-Shiang Chi
Journal:  Pediatr Nephrol       Date:  2003-10-24       Impact factor: 3.714

Review 4.  The treatment of systemic lupus proliferative nephritis.

Authors:  Marilynn G Punaro
Journal:  Pediatr Nephrol       Date:  2012-11-22       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.